Panmure Gordon reiterated their buy rating on shares of Vernalis plc (LON:VER) in a report released on Thursday. The brokerage currently has a GBX 76 ($0.99) price target on the stock.

VER has been the topic of a number of other research reports. Canaccord Genuity reaffirmed a buy rating and set a GBX 84 ($1.10) price target on shares of Vernalis plc in a research report on Tuesday, September 6th. Shore Capital reaffirmed a house stock rating on shares of Vernalis plc in a research report on Tuesday, July 19th. Finally, Stifel Nicolaus raised their price target on Vernalis plc from GBX 94 ($1.23) to GBX 99 ($1.29) and gave the stock a buy rating in a research report on Tuesday, September 6th. Four research analysts have rated the stock with a buy rating, Vernalis plc presently has an average rating of Buy and a consensus price target of GBX 80.20 ($1.05).

Shares of Vernalis plc (LON:VER) opened at 43.9375 on Thursday. Vernalis plc has a 52-week low of GBX 31.00 and a 52-week high of GBX 84.75. The company’s market capitalization is GBX 195.58 million. The stock has a 50 day moving average price of GBX 43.87 and a 200 day moving average price of GBX 46.28.

About Vernalis plc

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.